Company Filing History:
Years Active: 2022
Title: Emily Ann York: Innovator in Cancer Treatment
Introduction
Emily Ann York is a prominent inventor based in Allston, MA (US). She has made significant contributions to the field of cancer treatment through her innovative research and development of new therapeutic compounds. With a total of 2 patents, her work focuses on addressing critical challenges in oncology.
Latest Patents
Emily's latest patents include "Quinolin-2(1H)-one inhibitors of Late SV40 Factor" and "Heterocyclic LSF inhibitors and their uses." The first patent is directed to compositions, methods, and kits for the treatment of cancer, specifically hepatocellular carcinoma (HCC). This invention discloses the use of small-molecule compounds of Formula (I) to inhibit tubulin acetylation, thereby inhibiting cell migration and modulating cell compaction. The second patent focuses on heterocyclic SV40 Factor (LSF) inhibitors, detailing small-molecule compounds of Formula (I) that can be used in methods for inhibiting LSF in a subject and treating cancer.
Career Highlights
Emily Ann York is affiliated with Boston University, where she conducts her research and development work. Her innovative approach and dedication to cancer research have positioned her as a key figure in her field.
Collaborations
Emily collaborates with notable colleagues, including Scott Edward Schaus and Ulla Hansen. Their combined expertise enhances the research efforts and contributes to the advancement of cancer treatment methodologies.
Conclusion
Emily Ann York's contributions to cancer treatment through her patents and research at Boston University highlight her role as an influential inventor in the medical field. Her work continues to pave the way for innovative solutions in oncology.